Iron Deficiency Anemia Therapy Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams

June 18, 2025 06:42 PM AEST | By EIN Presswire
 Iron Deficiency Anemia Therapy Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 18, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

The iron deficiency anemia therapy market has witnessed strong growth in recent times, with its value expected to increase from $4.46 billion in 2024 to $4.82 billion in 2025 at a compound annual growth rate CAGR of 8.1%. The rise in the historical period can be ascribed to increased research and development activities, new drug developments, advancements in iron supplementation, the rising prevalence of iron deficiency anemia, a focus on social healthcare, and improvement in treatment options.

What Is The Projected Future Growth Of The Iron Deficiency Anemia Therapy Market Size?
In the next few years, further robust growth is anticipated to be seen in the iron deficiency anemia therapy market size. It is projected to rise to $6.51 billion in 2029 at a CAGR of 7.8%. The growth in the forecast period is due to several contributing factors, including increasing promotional activities, awareness programs, the expansion of specialized medicine pipelines, changes in nutrition and dietary habits, the expansion of iron-based therapy options, and an increase in maternal iron deficiency incidences.

Major trends in the forecast period include advancements such as iron-targeting nanotechnology, wearable health monitors, smart iron supplements, blood iron biosensors, and nanorobots for iron delivery. Rising cases of chronic diseases also act as a significant growth propellant for the iron deficiency anemia therapy market.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24265&type=smp

What Are The Key Drivers Propelling The Growth Of The Iron Deficiency Anemia Therapy Market?
Furthermore, the widespread prevalence of chronic diseases, which are often persistent for a year or more, contributes to the growing need for iron deficiency anemia therapy market. This incidence is largely due to increasing unhealthy lifestyles, such as poor dietary habits, physical inactivity, and tobacco use, leading to the emergence of conditions like obesity, diabetes, and heart disease.

These chronic conditions could hinder the body's ability to absorb iron properly, thereby raising the risk of iron deficiency and the need for supplementation or treatment to restore iron levels. In June 2024, The National Health Service, a UK-based government department, reported an 18% increase in the diagnosis of non-diabetic hyperglycemia, or pre-diabetes, with 3,615,330 individuals registering with a GP in 2023. Due to such reasons, increasing cases of chronic diseases are driving growth in the iron deficiency anemia therapy market.

What Key Player Strategies Are Driving The Iron Deficiency Anemia Therapy Market?
The players dominating the iron deficiency anemia therapy market include Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Akebia Therapeutics Inc., Otsuka Pharmaceutical Co Ltd, AdvaCare Pharma USA LLC, Apotex Inc., Ironic Biotech AB, KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-anemia-therapy-global-market-report

What Are The Emerging Trends In The Iron Deficiency Anemia Therapy Market?
A trend emerging within the iron deficiency anemia therapy market industry is the development of advancements in treatment options by major companies. They are focusing particularly on injectable formulations to enhance treatment efficacy and accessibility. An example includes the launch of Orofer FCM 750, developed by Emcure Pharmaceuticals Ltd., in May 2023, designed to treat iron deficiency and iron deficiency anemia IDA.

How Is The Iron Deficiency Anemia Therapy Market Segmented?
An analysis of the iron deficiency anemia therapy market segmentation reveals it to be split into several categories: by Product Type - Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide; by Therapy Type - Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types; by Therapy Areas - Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology; by Distribution Channel - Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies; by End User - Hospitals, Specialty Clinics, Home Care Setting, Other End Users.

Each category offers further subdivisions. For instance, the segment by Ferrous Sulphate offers Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations, while the segment by Ferrous Gluconate offers Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations, and so on.

What Are The Regional Insights In The Iron Deficiency Anemia Therapy Market?
In terms of geographical distribution, North America stood as the largest region in the iron deficiency anemia therapy market in 2024. In the forecast period, Asia-Pacific is anticipated to show the fastest growth rate.

Browse Through More Similar Reports By The Business Research Company:

Iron Deficiency Injectable Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

5-Alpha Reductase Deficiency Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.